Actin is required for endocytic trafficking in the malaria parasite Plasmodium falciparum.
The intra-erythrocytic stages of the malaria parasite endocytose large quantities of the surrounding erythrocyte cytoplasm and deliver it to a digestive food vacuole via endocytic vesicles. Digestion provides amino acids for parasite protein synthesis and is required to maintain the osmotic integrity of the host cell. The parasite endocytic pathway has been described morphologically by electron microscopy, but the molecular mechanisms that mediate and regulate it remain elusive. Given the involvement of actin in endocytosis in other eukaryotes, we have used actin inhibitors to assess the requirement for this protein in the endocytic pathway of the human malaria parasite, Plasmodium falciparum. Treatment of cultures with cytochalasin D did not affect haemoglobin levels in the parasites when co-administered with protease inhibitors, and neither did it affect the uptake of the endocytic tracer horseradish peroxidase, suggesting the absence of actin in the mechanism of endocytosis. However, in the absence of protease inhibitors, treated parasites contained increased levels of haemoglobin due to an accumulation of enlarged endocytic vesicles, as determined by immunofluorescence and electron microscopy, suggesting a role for actin in vesicle trafficking, possibly by mediating vesicle maturation and/or fusion to the digestive vacuole. In contrast to cytochalasin D, treatment with jasplakinolide led to an inhibition of endocytosis, an accumulation of vesicles closer to the plasma membrane and a marked concentration of actin in the parasite cortex. We propose that the stabilization of cortical actin filaments by jasplakinolide interferes with normal endocytic vesicle formation and migration from the cell periphery.
Smythe
Wynand A
WA
Division of Pharmacology and Institute of Infectious Diseases and Molecular Medicine, University of Cape Town Medical School, Cape Town, 7925, South Africa.
Joiner
Keith A
KA
Hoppe
Heinrich C
HC
D008841:Actin Cytoskeleton / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D000199:Actins / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D000818:Animals; D001692:Biological Transport / Q000502:physiology; D002478:Cells, Cultured; D015638:Cytochalasin D / Q000494:pharmacology; D047630:Depsipeptides / Q000494:pharmacology; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology*; D004912:Erythrocytes / Q000469:parasitology / Q000648:ultrastructure; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D046529:Microscopy, Electron, Transmission; D008856:Microscopy, Fluorescence; D010963:Plasmodium falciparum / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D011480:Protease Inhibitors / Q000494:pharmacology; D022161:Transport Vesicles / Q000378:metabolism / Q000502:physiology / Q000648:ultrastructure
D000199:Actins; D047630:Depsipeptides; D006454:Hemoglobins; D011480:Protease Inhibitors; C057531:jasplakinolide; D015638:Cytochalasin D